Articles related to EMERGING THERAPIES

A randomized trial found greater symptom improvement with single-dose intranasal mebufotenin than with a low-dose control in treatment-resistant depression. Most higher-dose recipients met discharge criteria within two hours; longer-term outcomes remain uncertain.

Topical presbyopia options differ in reported efficacy, duration, and adverse-effect profiles, according to an expert review of phase 3 data and clinical considerations presented at the 2026 American Academy of Optometry meeting.

A novel liposomal drug-delivery system prolonged tetrodotoxin nerve blockade to two to three weeks in rats, substantially exceeding currently available formulations. The findings highlight a potential strategy for sustained local anesthetic delivery, although clinical relevance remains unproven pending human validation.

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.

An experimental cell therapy that couples a patient’s red blood cells with myelin protein fragments was well tolerated in a 10-patient Phase 1b study and was associated with increases in regulatory T-cells and reductions in neurofilament light chain, a biomarker linked to nerve injury.

An early clinical experience report describes how one retina practice integrated photobiomodulation (PBM) for intermediate age-related macular degeneration, highlighting workflow considerations, patient selection challenges, reimbursement issues, and ongoing uncertainty regarding long-term benefit.